amgen Archives - Cardiovascular News

The European Commission authorise use of evolocumab to reduce risk of myocardial infarction in patients with established cardiovascular disease

31st May 2018

The European Commissi...

EBBINGHAUS trial shows non-inferiority of evolocumab for cognitive function in cardiovascular group

21st March 2017

Amgen has announced d...

ACC 2017: PCSK9 inhibitor evolocumab significantly reduces the risk of cardiovascular events

21st March 2017

Data for a new drug t...

Evolocumab significantly reduces risk of cardiovascular events

3rd February 2017

The FOURIER trial eva...

AHA 2016: Two thirds of patients experience plaque regression with the PCSK9 inhibitor evolocumab

16th November 2016

Amgen has announced t...

Positive top-line results from phase 3 GLAGOV imaging study of evolocumab

21st September 2016

The Phase 3 GLAGOV (G...

Write to us
Editorial: Will Date will@bibamedical.com
Advertising: Hannah Shiels hannah@bibamedical.com

BIBA Medical, Europe
526 Fulham Road, Fulham, London, SW6 5NR
TEL: +44 (0)20 7736 8788
Email: info@bibamedical.com

Terms and Conditions | Privacy Policy